Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 33210573)

  • 1. EGFR and anti-EGFR nanobodies: review and update.
    Sharifi J; Khirehgesh MR; Safari F; Akbari B
    J Drug Target; 2021 Apr; 29(4):387-402. PubMed ID: 33210573
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Anti-EGFR Binding Nanobody Delivery System to Improve the Diagnosis and Treatment of Solid Tumours.
    Wang L; Zhang G; Qin L; Ye H; Wang Y; Long B; Jiao Z
    Recent Pat Anticancer Drug Discov; 2020; 15(3):200-211. PubMed ID: 32885759
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immunotoxins and nanobody-based immunotoxins: review and update.
    Khirehgesh MR; Sharifi J; Safari F; Akbari B
    J Drug Target; 2021 Sep; 29(8):848-862. PubMed ID: 33615933
    [TBL] [Abstract][Full Text] [Related]  

  • 4. EGFR-Targeted Nanobody Functionalized Polymeric Micelles Loaded with mTHPC for Selective Photodynamic Therapy.
    Liu Y; Scrivano L; Peterson JD; Fens MHAM; Hernández IB; Mesquita B; Toraño JS; Hennink WE; van Nostrum CF; Oliveira S
    Mol Pharm; 2020 Apr; 17(4):1276-1292. PubMed ID: 32142290
    [No Abstract]   [Full Text] [Related]  

  • 5. Single chain epidermal growth factor receptor antibody conjugated nanoparticles for in vivo tumor targeting and imaging.
    Yang L; Mao H; Wang YA; Cao Z; Peng X; Wang X; Duan H; Ni C; Yuan Q; Adams G; Smith MQ; Wood WC; Gao X; Nie S
    Small; 2009 Feb; 5(2):235-43. PubMed ID: 19089838
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Targeted delivery of 5-fluorouracil-1-acetic acid (5-FA) to cancer cells overexpressing epithelial growth factor receptor (EGFR) using virus-like nanoparticles.
    Gan BK; Rullah K; Yong CY; Ho KL; Omar AR; Alitheen NB; Tan WS
    Sci Rep; 2020 Oct; 10(1):16867. PubMed ID: 33033330
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Molecular and functional insight into anti-EGFR nanobody: Theranostic implications for malignancies.
    Tripathy RK; Pande AH
    Life Sci; 2024 May; 345():122593. PubMed ID: 38554946
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Aminoflavone-loaded EGFR-targeted unimolecular micelle nanoparticles exhibit anti-cancer effects in triple negative breast cancer.
    Brinkman AM; Chen G; Wang Y; Hedman CJ; Sherer NM; Havighurst TC; Gong S; Xu W
    Biomaterials; 2016 Sep; 101():20-31. PubMed ID: 27267625
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tumor Targeting of Polymeric Nanoparticles Conjugated with Peptides, Saccharides, and Small Molecules for Anticancer Drugs.
    Bayram B; Ozgur A; Tutar L; Tutar Y
    Curr Pharm Des; 2017; 23(35):5349-5357. PubMed ID: 28911307
    [TBL] [Abstract][Full Text] [Related]  

  • 10. HER1/EGFR-targeted agents: predicting the future for patients with unpredictable outcomes to therapy.
    Giaccone G
    Ann Oncol; 2005 Apr; 16(4):538-48. PubMed ID: 15746148
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Preparation and characterization of humanized nanobodies targeting the dimer interface of epidermal growth factor receptor (EGFR).
    Zhu H; Zhao L; Li Z; Wen B; Qiu C; Liu M; Xu Z; Hu S; Li H
    Protein Expr Purif; 2019 May; 157():57-62. PubMed ID: 30735705
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Epidermal growth factor receptor: is a novel therapeutic target for pancreatic cancer?
    Dhar A; Mehta S; Banerjee S; Dhar K; Dhar G; Sengupta K; Ray G; Banerjee SK; Campbell DR
    Front Biosci; 2005 May; 10():1763-7. PubMed ID: 15769665
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Anti-EGFR strategies as an incremental step for the treatment of colorectal cancer patients: moving from scientific evidence to clinical practice.
    Scartozzi M; Pierantoni C; Berardi R; Squadroni M; Cascinu S
    Expert Opin Ther Targets; 2006 Apr; 10(2):281-7. PubMed ID: 16548776
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Therapeutic efficacy and safety of paclitaxel/lonidamine loaded EGFR-targeted nanoparticles for the treatment of multi-drug resistant cancer.
    Milane L; Duan Z; Amiji M
    PLoS One; 2011; 6(9):e24075. PubMed ID: 21931642
    [TBL] [Abstract][Full Text] [Related]  

  • 15. EGFR-targeted immunoliposomes derived from the monoclonal antibody EMD72000 mediate specific and efficient drug delivery to a variety of colorectal cancer cells.
    Mamot C; Ritschard R; Küng W; Park JW; Herrmann R; Rochlitz CF
    J Drug Target; 2006 May; 14(4):215-23. PubMed ID: 16777680
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Targeted delivery of methotrexate to epidermal growth factor receptor-positive brain tumors by means of cetuximab (IMC-C225) dendrimer bioconjugates.
    Wu G; Barth RF; Yang W; Kawabata S; Zhang L; Green-Church K
    Mol Cancer Ther; 2006 Jan; 5(1):52-9. PubMed ID: 16432162
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Role of EGFR Monoclonal Antibodies in the Management of Non-small Cell Lung Cancer.
    Takeda M; Nakagawa K
    Curr Cancer Drug Targets; 2015; 15(9):792-802. PubMed ID: 26567882
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Anti-EGF Receptor Aptamer-Guided Co-Delivery of Anti-Cancer siRNAs and Quantum Dots for Theranostics of Triple-Negative Breast Cancer.
    Kim MW; Jeong HY; Kang SJ; Jeong IH; Choi MJ; You YM; Im CS; Song IH; Lee TS; Lee JS; Lee A; Park YS
    Theranostics; 2019; 9(3):837-852. PubMed ID: 30809312
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A biparatopic anti-EGFR nanobody efficiently inhibits solid tumour growth.
    Roovers RC; Vosjan MJ; Laeremans T; el Khoulati R; de Bruin RC; Ferguson KM; Verkleij AJ; van Dongen GA; van Bergen en Henegouwen PM
    Int J Cancer; 2011 Oct; 129(8):2013-24. PubMed ID: 21520037
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Paper Title "Hu7CG2: A Novel Humanized Anti-Epidermal Growth Factor Receptor (EGFR) Biparatopic Nanobody".
    Sharifi J; Khirehgesh MR; Akbari B; Soleymani B; Mansouri K
    Mol Biotechnol; 2021 Jun; 63(6):525-533. PubMed ID: 33772436
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.